JPS58177668A - Body liquid purifying apparatus - Google Patents
Body liquid purifying apparatusInfo
- Publication number
- JPS58177668A JPS58177668A JP57059755A JP5975582A JPS58177668A JP S58177668 A JPS58177668 A JP S58177668A JP 57059755 A JP57059755 A JP 57059755A JP 5975582 A JP5975582 A JP 5975582A JP S58177668 A JPS58177668 A JP S58177668A
- Authority
- JP
- Japan
- Prior art keywords
- body fluid
- fluid purification
- purification means
- target substance
- outlet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title 1
- 210000001124 body fluid Anatomy 0.000 claims description 81
- 239000010839 body fluid Substances 0.000 claims description 81
- 238000000746 purification Methods 0.000 claims description 42
- 238000000605 extraction Methods 0.000 claims 1
- 239000013076 target substance Substances 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 7
- 210000000601 blood cell Anatomy 0.000 description 6
- 230000006866 deterioration Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000010586 diagram Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】
本発明は、体液の浄化装置に関する。さらに詳しくは、
体液中に発現する、生体にとって有害な物質を除去する
装置に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a body fluid purification device. For more details,
The present invention relates to a device for removing substances harmful to living organisms that are expressed in body fluids.
近年、医学の進歩によシ、人工臓器分野の著しい進歩が
与られ、体液中に発現あるいは蓄積された生体にとって
有害な物質を特異的に除去することが可能となシ、数多
くの生命が救われるようになってきた。In recent years, advances in medicine have led to significant advances in the field of artificial organs, making it possible to specifically remove substances that are harmful to living organisms expressed or accumulated in body fluids, and many lives have been saved. It's starting to get worse.
例を挙げると、透析膜を用いて、腎炎患者の体液中に蓄
積された、低分子量物質を除去してやる人工腎臓、薬物
中毒患者、肝炎患者の体液から、活性炭を用いて毒物を
除去してやる人工肝補助装置などが挙げられ、一部の変
性した蛋白質やビリルビン、自己に対する抗体、免疫複
合体などを吸着除去することにより、肝炎、腎炎等の疾
患および慢性間接リウマチ、全身性エリテマトーデス等
の免疫疾患の治療に用いる試み、あるい祉血液中から一
部の血球を除去する試み等もなされるようＫなってきた
。Examples include an artificial kidney that uses a dialysis membrane to remove low-molecular weight substances accumulated in the body fluids of nephritis patients, and an artificial liver that uses activated carbon to remove toxic substances from the body fluids of drug addicts and hepatitis patients. These include auxiliary devices, which adsorb and remove some denatured proteins, bilirubin, antibodies against self, immune complexes, etc., thereby preventing diseases such as hepatitis and nephritis, and immune diseases such as chronic rheumatoid arthritis and systemic lupus erythematosus. Attempts have also been made to use them for treatment or to remove some blood cells from blood.
従来、このような目的を達成するための装置については
、体液の分析手段を体液浄化手段の前後に有するものが
なかった。そのため、体液浄化手段の性能劣化、すなわ
ち、透析膜、濾過膜等の物質透過性能の劣化、吸着材の
吸着性能劣化、血球分離フィルターの血球捕捉能の劣化
等を監視することができなかった。したがって、仮に能
力（効率）の低下した体液浄化手段を用いて、効率の悪
い体液浄化を長時間性なっていても、その事実を把握で
きないのが現状であった。このよう表条件で患者に対す
る体外循環体液浄化治療を続けることは、患者に対する
侵襲の点で好ましくない。Conventionally, there has been no apparatus for achieving this purpose that has body fluid analysis means before and after body fluid purification means. Therefore, it has not been possible to monitor performance deterioration of the body fluid purification means, that is, deterioration of substance permeation performance of dialysis membranes, filtration membranes, etc., deterioration of adsorption performance of adsorbents, deterioration of blood cell capture ability of blood cell separation filters, etc. Therefore, even if a body fluid purification means with a reduced capacity (efficiency) is used to perform body fluid purification inefficiently for a long time, it is currently impossible to grasp this fact. Continuing extracorporeal circulation body fluid purification treatment for a patient under such conditions is not preferable in terms of invasiveness to the patient.
本発明の目的は、上記したような装置上の不備に基づく
欠点を改良し、体液浄化手段の性能変化を常に把掴でき
、さらＫは、どれ位の量の除去対象物質を除去できたか
を連続的に監視することが可能で、体液浄化を効率的に
、かつ安全に行表うことができる体液浄化装置を提供す
ることにある。The purpose of the present invention is to improve the above-mentioned drawbacks due to defects in the equipment, to be able to constantly grasp changes in the performance of the body fluid purification means, and to be able to monitor how much of the target substance has been removed. It is an object of the present invention to provide a body fluid purification device that can be continuously monitored and can perform body fluid purification efficiently and safely.
本発明者らは、上記目的に沿って鋭意検討し、本発明を
完成するに至った０
すなわち、本発明は、体液の導入口と導出口との間に体
液浄化手段を有し、かつ体液浄化手段の体液入口側およ
び出口側に体液の分析手段を有することを特徴とする体
液浄化装置である。The present inventors have made extensive studies in accordance with the above objectives and have completed the present invention. In other words, the present invention has a body fluid purification means between a body fluid inlet and a body fluid outlet, and This body fluid purification device is characterized by having body fluid analysis means on the body fluid inlet side and outlet side of the purification means.
本発明で言う体液とは、血液、血漿、腹水、リンパ液等
の生体液性成分を言い、血球のような固形成分を含んで
いるものを含む。The body fluid referred to in the present invention refers to biological fluid components such as blood, plasma, ascites, and lymph, and includes those containing solid components such as blood cells.
体液の導入口、導出口とは、体液を体液浄化手段に導き
、体液浄化手段で浄化された体液を外部に導き出すだめ
の手段でアシ、塩化ビニール、シリコン等のチューブが
使用できる。また、該チューブの一部にバブルトラップ
、ポンプ接続用のチューブ等の部品が含まれていてもよ
い。The body fluid inlet and outlet are means for guiding the body fluid to the body fluid purification means and for guiding the body fluid purified by the body fluid purification means to the outside, and tubes made of reed, vinyl chloride, silicone, etc. can be used. Moreover, parts such as a bubble trap and a tube for connecting a pump may be included in a part of the tube.
体液浄化手段とは、体液から目的とする物質を透析、ヂ
過、吸着、粘着などの手段により除去するだめの手段を
言い、人工腎臓用の透析膜を用いた透析器、沖過膜を用
いたｐ過器、吸着材を用いた吸着器、繊維を充填したデ
イプス・フィルター等を含み、これらを組合せたもの、
濃縮器等、上記した以外の手段との組合せ本含む０
体液の分析手段とは、体液中の蛋白質、中分子量物質、
低分子量物質、血球等、除去対象の目的物質を定量する
手段、または半定量（例えば、目的物質の活性測定、抗
体の場合の抗体価測定等）を行なう手段を言い、除去対
象目的物質によって分析：手段は最適な方法が採用され
る。Body fluid purification means refers to means for removing target substances from body fluids by means such as dialysis, filtration, adsorption, or adhesion. Including filters using filters, adsorbers using adsorbents, depth filters filled with fibers, etc., and combinations of these,
This includes combinations with means other than those mentioned above, such as concentrators.Methods for analyzing body fluids include proteins in body fluids, medium molecular weight substances,
A method for quantifying target substances to be removed, such as low molecular weight substances and blood cells, or a means for semi-quantitative measurement (e.g., measuring the activity of the target substance, measuring antibody titer in the case of antibodies, etc.), and is used for analysis depending on the target substance to be removed. :The most suitable method will be adopted.
以下、例示すると、目的物質が蛋白質の場合は、屈折率
計による方法が簡便であシ、より精密には吸光度を測定
することによって可能である。また、体液中にある物質
で分子量がある特定の範囲にある物質を定量するために
は、高速液体クロマトグラフィーの装置が有効に用いら
れる。目的物質が血球の場合は、電気抵抗を利用した自
動血球計数器が有効に利用できる。For example, when the target substance is a protein, a method using a refractometer is simple and can be performed more precisely by measuring absorbance. Furthermore, a high-performance liquid chromatography device is effectively used to quantify substances in body fluids whose molecular weights fall within a certain range. If the target substance is blood cells, an automatic hematology counter that uses electrical resistance can be effectively used.
体液の分析手段に要求される性能は、（１）目的物質の
定量ができること、（２）分析で捨てられてしまう体液
の量が微量であるか′、または捨てずに返却できるとと
、（３）分析に必要な時間が短いこと、（４）必要とす
る分析精度があることであるが、これらの要件を満たせ
ば、体液浄化操作を行なっている最中に、体液浄化手段
の前後における体液中の目的物質濃度を監視することが
でき、必要に応じ計算回路を通して目的物質の除去量、
体液浄化手段の能力を知ることができる。Performance requirements for body fluid analysis means include (1) being able to quantify the target substance, (2) whether the amount of body fluid that is discarded during analysis is very small, or whether it can be returned without being discarded. 3) The time required for analysis is short; and (4) the required analytical accuracy is met. The concentration of the target substance in body fluids can be monitored, and if necessary, the amount of target substance removed can be determined through a calculation circuit.
You can know the ability of body fluid purification means.
また、この結果をもとにし、制御回路を通して体液浄化
手段の運転条件をコントロールすることも可能である。Furthermore, based on this result, it is also possible to control the operating conditions of the body fluid purification means through a control circuit.
以下、図面を用いて本発明の体液浄化装置をさらに詳細
に説明する。第１同社本発明の体液浄化装置の基本構成
を示す模式図であり、第２図は体液の分析手段として高
速液体クロマトグラフィーを用いた例を示す模式図であ
る。Hereinafter, the body fluid purification device of the present invention will be explained in more detail using the drawings. FIG. 1 is a schematic diagram showing the basic configuration of the body fluid purification device of the present invention, and FIG. 2 is a schematic diagram showing an example in which high performance liquid chromatography is used as a means for analyzing body fluids.
本発明の体液浄化装置は、基本的には第１図に示すよう
に、体液の導入口１と導出口２との間に体液浄化手段３
を有し、かつ体液浄化手段３０体液人口４側および出口
５側に体液の分析手段６．７を有する。分析手段６．７
Ｌ独立して２台の装置であってもよいし、装置としては
１台で体液のサンプリングを交互に行なう方式をとって
もよい。体液は導入口１から導入され、体液浄化手段３
に送られ、ここで除去対象目的物質が除去され、浄化さ
れた血漿が導出口２から導き出される。この体液の流れ
の中で、体液浄化手段３の前後で分析装置６．７により
、目的物質の体液中濃度を測定する。その分析結果によ
り、体液浄化手段３の能力の劣化具合がわかるのである
。Basically, the body fluid purification device of the present invention has a body fluid purification means 3 between a body fluid inlet 1 and a body fluid outlet 2, as shown in FIG.
and body fluid analysis means 6.7 on the body fluid purification means 30 body fluid population 4 side and outlet 5 side. Analysis means 6.7
There may be two independent devices, or a system may be used in which body fluid sampling is alternately performed using one device. Body fluid is introduced through the inlet port 1, and the body fluid purification means 3
The target substance to be removed is removed there, and the purified plasma is led out from the outlet 2. In this flow of body fluid, the concentration of the target substance in the body fluid is measured before and after the body fluid purification means 3 by the analyzer 6.7. Based on the analysis results, the degree of deterioration of the performance of the body fluid purification means 3 can be determined.
第２図は分析手段に高速液体クロマトグラフィーを用い
た例である。FIG. 2 is an example in which high performance liquid chromatography is used as the analytical means.
導入口１から導入された体液け、体液浄化手段３の入口
４側でポンプ８により弁９を通してサンプリングされ、
分離カラム１２へ送られる。The body fluid introduced from the inlet 1 is sampled through the valve 9 by the pump 8 on the inlet 4 side of the body fluid purification means 3,
It is sent to separation column 12.
次いで、緩衝液１０が弁１１を通してポンプ８によシ分
離カラム１２へ送られる。分離カラム１２で分離された
体液は、検出器１３で分析され、濃度が測定される。そ
の後、体液は緩衝液ＩＯとともに排出口１４から捨てら
れる。次に、初めのサンプリングの時点から分離用カラ
ム１２で体液を分離するのに要する時間を隔てた後に、
体液浄化手段３で浄化された体液が、体液浄化手段３の
出口５側でポンプ８によシ弁１５を通してサンプリング
され、前記しだのと同様の経路で濃度が分析され、濃度
が測定される。この体液浄化手段３の前後の濃度の電気
信号を必要に応じて演算回路１６に送り、体液浄化手段
３の劣化程度、体液浄化手段３によって浄化された目的
物質の素々どを知ることができる。さらに１必要があれ
ば制御回路１７により、体液浄化手段３の運転条件を制
御することもできる。Buffer 10 is then pumped through valve 11 by pump 8 to separation column 12 . The body fluid separated by the separation column 12 is analyzed by the detector 13 and its concentration is measured. The body fluid is then discarded through the outlet 14 along with the buffer solution IO. Next, after a period of time required to separate the body fluid in the separation column 12 from the time of initial sampling,
The body fluid purified by the body fluid purification means 3 is sampled by the pump 8 through the valve 15 on the outlet 5 side of the body fluid purification means 3, and its concentration is analyzed and measured through the same route as the above-mentioned sinter. . Electrical signals of the concentrations before and after the body fluid purification means 3 are sent to the calculation circuit 16 as needed, so that the degree of deterioration of the body fluid purification means 3 and the nature of the target substance purified by the body fluid purification means 3 can be known. . Furthermore, if necessary, the operating conditions of the body fluid purification means 3 can be controlled by the control circuit 17.
以上述べたように、本発明の体液浄化装置を使用するこ
とにより、体液浄化手段の性能変化を常に把握すること
ができ、さらには、どれ位の量の除去対象物質を除去で
きたかの監視を連続的に行なうことが可能で、体液浄化
を効率的に、かつ安全に行なうことができるようになっ
た。また、本発明の体液浄化装置は、体液浄化手段が吸
着材を使用したものである場合、特に有効に使用できる
。As described above, by using the body fluid purification device of the present invention, it is possible to constantly grasp changes in the performance of the body fluid purification means, and furthermore, it is possible to continuously monitor how much of the target substance has been removed. It has become possible to perform body fluid purification efficiently and safely. Further, the body fluid purification device of the present invention can be used particularly effectively when the body fluid purification means uses an adsorbent.
第１図は本発明の体液浄化装置の基本構成を示す模式図
、第２図は体液の分析装置に高速液体クロマトグラフィ
ーを用いた例を示す模式図である。
ｌ・・・体液導入口、２・・・体液導出口、３・・・体
液浄化手段、４・・・入口、５・・・出口、６．７・・
・分析・ニ一
手段、８・・・ポンプ、９．１１．１５・・・弁、１ｏ
・・緩衝液、１２・・・分離カラム、１３・・・検出器
、１４・・・排出口、１６・・演算回路、１７・・・制
御回路。FIG. 1 is a schematic diagram showing the basic configuration of the body fluid purification device of the present invention, and FIG. 2 is a schematic diagram showing an example in which high performance liquid chromatography is used in the body fluid analysis device. l... Body fluid inlet, 2... Body fluid outlet, 3... Body fluid purification means, 4... Inlet, 5... Outlet, 6.7...
・Analysis・21 means, 8...Pump, 9.11.15...Valve, 1o
... Buffer solution, 12 ... Separation column, 13 ... Detector, 14 ... Discharge port, 16 ... Arithmetic circuit, 17 ... Control circuit.
Claims (1)
つ体液浄化手段の体液入口側および出口側に体液の外析
手段を有することを特徴とする体液浄化装置。A body fluid purification device comprising a body fluid purification means between a body fluid inlet and an outlet, and a body fluid external extraction means on the body fluid inlet side and outlet side of the body fluid purification means.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57059755A JPS58177668A (en) | 1982-04-12 | 1982-04-12 | Body liquid purifying apparatus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57059755A JPS58177668A (en) | 1982-04-12 | 1982-04-12 | Body liquid purifying apparatus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS58177668A true JPS58177668A (en) | 1983-10-18 |
Family
ID=13122383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57059755A Pending JPS58177668A (en) | 1982-04-12 | 1982-04-12 | Body liquid purifying apparatus |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58177668A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019042088A (en) * | 2017-08-31 | 2019-03-22 | 日東電工株式会社 | Management system of drain drainage |
-
1982
- 1982-04-12 JP JP57059755A patent/JPS58177668A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019042088A (en) * | 2017-08-31 | 2019-03-22 | 日東電工株式会社 | Management system of drain drainage |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5858238A (en) | Salvage of autologous blood via selective membrane/sorption technologies | |
| Gros et al. | The diffusion of carbon dioxide in erythrocytes and hemoglobin solutions | |
| CA1086235A (en) | Continuous removing system of blood substances by extra corporeal circulation | |
| EP0111696A2 (en) | An arrangement for the removal of one or more fractions out of whole blood, plasma or other similar body fluids | |
| JP2016531660A (en) | Cross flow filtration device | |
| CN1090511A (en) | The hemodialysis monitoring system that is used for hemodialyzer | |
| EP0418440A1 (en) | Cartridge and cartridge assembly | |
| JP5249905B2 (en) | Clinical laboratory system and clinical laboratory method | |
| JP4495221B2 (en) | Device for removing substances from liquids, especially blood | |
| KR20120121883A (en) | Device and method for biological sample purification and enrichment | |
| US3483990A (en) | Dialyzer apparatus | |
| Milly et al. | Selenium in renal failure patients | |
| JPH0197857A (en) | Automatic measuring method of glycosylated hemoglobin and sample introducing valve | |
| JPS58177668A (en) | Body liquid purifying apparatus | |
| Dowty et al. | Gas chromatographic mass spectrometric computer analysis of volatile components in blood plasma from hemodialysis patients | |
| JP2006343220A (en) | Pretreatment method of biocomponent-containing solution and analysis solution purification method | |
| JP3018032B2 (en) | Automatic method for measuring glycohemoglobin | |
| RU222240U1 (en) | Blood sample collection device to evaluate the effectiveness of extracorporeal detoxification | |
| Ravin et al. | Blood-gas transfer, hemolysis, and diffusing capacity in a bubble tonometer | |
| JPH0774799B2 (en) | Method for measuring blood components | |
| CN214032445U (en) | Saliva sample nucleic acid purifier | |
| JPS5854130B2 (en) | Leukocyte separation method | |
| Hirayama et al. | Oxidative stress during leukocyte absorption apheresis | |
| CN111655320B (en) | Device for selectively removing molecules from tissue or fluid | |
| Faguer et al. | Improved separation and quantification of the" middle molecule" b4-2 in uremia. |